Menu Search
Equities

Theravance Biopharma Inc

0TB:DUS

Theravance Biopharma Inc

Actions
  • Price (EUR)8.15
  • Today's Change0.20 / 2.52%
  • Shares traded0.00
  • 1 Year change-15.10%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 18:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Theravance Biopharma Inc had net income fall from a gain of 872.13m to a loss of 55.19m despite a 11.84% increase in revenues from 51.35m to 57.42m.
Gross margin--
Net profit margin-73.61%
Operating margin-67.58%
Return on assets-11.29%
Return on equity-19.27%
Return on investment-12.00%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Theravance Biopharma Inc fell by 258.63m. In addition, the company used more cash to support its operations than it earned, posting a cash flow loss of 27.00m. In addition the company used 32.70m on investing activities and also paid 198.93m in financing cash flows.
Cash flow per share-0.885
Price/Cash flow per share--
Book value per share3.96
Tangible book value per share3.96
More ▼

Balance sheet in USDView more

Theravance Biopharma Inc has a Debt to Total Capital ratio of 13.05%, a higher figure than the previous year's 9.48%.
Current ratio5.20
Quick ratio--
Total debt/total equity0.150
Total debt/total capital0.1305
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.